# LMAT — LeMaitre Vascular, Inc. · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** LMAT  
**Sources:** 18  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-lmat-lemaitre-vascular-inc-catalysts-narrative-risks-6139

---

# LeMaitre Vascular, Inc. (NASDAQ: LMAT) — Company Profile

LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery (peripheral vascular disease), including vascular grafts, catheters, patches, valvulotomes, and carotid shunts, serving the Americas, Europe, the Middle East, Africa, and Asia Pacific [[16]](https://stockanalysis.com/stocks/lmat/). Founded in 1986 and headquartered in Burlington, Massachusetts, it is led by chairman/CEO George W. LeMaitre [[20]](https://en.wikipedia.org/wiki/LeMaitre_Vascular). A minor correction to our own calendar: the listing exchange is **Nasdaq** (NASDAQ:LMAT), not "NGM" [[1]](https://finance.yahoo.com/markets/stocks/articles/lemaitre-vascular-inc-lmat-q2-050207267.html), [[9]](https://finance.yahoo.com/healthcare/articles/lemaitre-vascular-lmat-q2-2026-003002143.html), [[14]](https://finance.yahoo.com/markets/stocks/articles/speculative-rally-weighed-lemaitre-vascular-130603141.html), [[20]](https://en.wikipedia.org/wiki/LeMaitre_Vascular).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-lmat-lemaitre-vascular-inc-catalysts-narrative-risks-6139 (free to sign up)._
